217 related articles for article (PubMed ID: 37418832)
1. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE; Miller A; Soslow RA; Lankes HA; DeLair D; Segura S; Chavan S; Zamarin D; DeBernardo R; Moore K; Moroney J; Shahin M; Thaker PH; Wahner-Hendrickson AE; Aghajanian C
Gynecol Oncol; 2023 Sep; 176():16-24. PubMed ID: 37418832
[TBL] [Abstract][Full Text] [Related]
2. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
3. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
4. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
Lowery WJ; Schildkraut JM; Akushevich L; Bentley R; Marks JR; Huntsman D; Berchuck A
Int J Gynecol Cancer; 2012 Jan; 22(1):9-14. PubMed ID: 22193641
[TBL] [Abstract][Full Text] [Related]
5. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
[TBL] [Abstract][Full Text] [Related]
6. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
7. BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer.
Stamp JP; Gilks CB; Wesseling M; Eshragh S; Ceballos K; Anglesio MS; Kwon JS; Tone A; Huntsman DG; Carey MS
Int J Gynecol Cancer; 2016 Jun; 26(5):825-32. PubMed ID: 27051059
[TBL] [Abstract][Full Text] [Related]
8. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.
Fadare O; Gwin K; Desouki MM; Crispens MA; Jones HW; Khabele D; Liang SX; Zheng W; Mohammed K; Hecht JL; Parkash V
Mod Pathol; 2013 Aug; 26(8):1101-10. PubMed ID: 23524907
[TBL] [Abstract][Full Text] [Related]
10. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller RE; Brough R; Bajrami I; Williamson CT; McDade S; Campbell J; Kigozi A; Rafiq R; Pemberton H; Natrajan R; Joel J; Astley H; Mahoney C; Moore JD; Torrance C; Gordan JD; Webber JT; Levin RS; Shokat KM; Bandyopadhyay S; Lord CJ; Ashworth A
Mol Cancer Ther; 2016 Jul; 15(7):1472-84. PubMed ID: 27364904
[TBL] [Abstract][Full Text] [Related]
12. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
[TBL] [Abstract][Full Text] [Related]
13. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Banerjee S; Stewart J; Porta N; Toms C; Leary A; Lheureux S; Khalique S; Tai J; Attygalle A; Vroobel K; Lord CJ; Natrajan R; Bliss J
Int J Gynecol Cancer; 2021 Nov; 31(11):1471-1475. PubMed ID: 34518240
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
17. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
[TBL] [Abstract][Full Text] [Related]
18. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
Xiao W; Awadallah A; Xin W
Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
[TBL] [Abstract][Full Text] [Related]
19. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
[TBL] [Abstract][Full Text] [Related]
20. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.
Borrelli GM; Abrão MS; Taube ET; Darb-Esfahani S; Köhler C; Chiantera V; Mechsner S
Mol Hum Reprod; 2016 May; 22(5):329-37. PubMed ID: 26832958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
